openPR Logo
Press release

Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative Drug Development And Approvals Transform Myelodysplastic Syndrome (MDS) Treatment Market

02-07-2025 06:54 AM CET | Health & Medicine

Press release from: The Business Research Company

Myelodysplastic Syndrome MDS Drugs Market

Myelodysplastic Syndrome MDS Drugs Market

What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.

The myelodysplastic syndrome (MDS) drugs market is expected to grow to $5.12 billion by 2029 at a CAGR of 8.2%. Growth drivers include genomic research, immunotherapies, the global expansion of healthcare, and biomarker identification. Key trends include personalized medicine, combinatorial therapies, symptom management, and increased data sharing and collaboration.

What Is Driving the Growth Trajectory of the Myelodysplastic Syndrome (MDS) Drugs Market?
The increasing exposure to cancer treatments, such as chemotherapy and radiation, is projected to accelerate the expansion of the myelodysplastic syndrome (MDS) drug market in the coming years. Chemotherapy involves the use of drugs to destroy cancer cells, whereas radiation therapy utilizes high doses of radiation to eliminate cancer cells and shrink tumors. These treatments negatively impact the bone marrow's stem cells responsible for producing new blood cells, disrupting the natural cell production process and leading to the onset of MDS. Myelodysplastic syndrome (MDS) drugs play a crucial role in managing and treating MDS, a condition marked by irregular blood cell production in the bone marrow. For instance, based on the ESTRO-HERO (Health Economics in Radiation Oncology) analysis conducted by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, projections for 2025 indicate a 16% rise in radiotherapy treatment courses. As a result, increasing exposure to cancer treatments such as chemotherapy and radiation is propelling the expansion of the myelodysplastic syndrome (MDS) drug market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Which Leading Companies Are Shaping the Growth of the Myelodysplastic Syndrome (MDS) Drugs Market?
Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

What Are the Major Trends Shaping the Myelodysplastic Syndrome (MDS) Drugs Market?
Leading companies in the myelodysplastic syndrome (MDS) drugs market are developing innovative solutions, such as targeted therapies, to enhance patient care, meet customer needs, and integrate with existing treatment frameworks. Targeted therapy for MDS involves drugs that specifically address genetic mutations or molecular abnormalities in cancer cells, improving outcomes by attacking diseased cells while minimizing harm to healthy ones. For example, in October 2023, the FDA approved Tibsovo (ivosidenib) for adults with relapsed or refractory (R/R) MDS carrying an isocitrate dehydrogenase-1 (IDH1) mutation. This approval was based on an open-label, single-arm, multicenter study involving 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

What Are the Key Segments of the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented -

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs
2) By Route Of Administration: Oral, Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents
2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Which Region Dominates the Myelodysplastic Syndrome (MDS) Drugs Market?
North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Myelodysplastic Syndrome (MDS) Drugs Global Market Report?

- Market Size Analysis: Analyze the Myelodysplastic Syndrome (MDS) Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Myelodysplastic Syndrome (MDS) Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Myelodysplastic Syndrome (MDS) Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Myelodysplastic Syndrome (MDS) Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13043

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative Drug Development And Approvals Transform Myelodysplastic Syndrome (MDS) Treatment Market here

News-ID: 3855537 • Views:

More Releases from The Business Research Company

Global Pachymeter Device Market to Reach $24.73 Billion by 2029, Growing at 5.02% CAGR
Global Pachymeter Device Market to Reach $24.73 Billion by 2029, Growing at 5.02 …
What industry-specific factors are fueling the growth of the pachymeter device market? The growing prevalence of ocular diseases is expected to drive the expansion of the pachymeter device market in the coming years. Ocular diseases, which include a variety of conditions affecting the eye and its related structures, are on the rise due to factors like increased contact lens use, lifestyle changes, gender differences, and vitamin deficiencies. Pachymetry devices are crucial
In-Depth Analysis of the Specialty Pesticides Market: Growth Opportunities, Key Trends, and Forecast 2025-2034
In-Depth Analysis of the Specialty Pesticides Market: Growth Opportunities, Key …
What Are the Projected Growth and Market Size Trends for the Specialty Pesticides Market? There has been robust growth in the specialty pesticides market in the recent past. The forecast is that it will expand from $142.86 billion in 2024 to $150.13 billion in 2025, marking a compound annual growth rate (CAGR) of 5.1%. Factors contributing to growth in the historic period include a heightened demand for crop protection, the spread
Major Market Shift in Oncology Molecular Diagnostics Industry: Revolutionizing Oncology Molecular Diagnostics Through Advanced Genomics Technology
Major Market Shift in Oncology Molecular Diagnostics Industry: Revolutionizing O …
What Is the Forecasted Market Size and Growth Rate for the Oncology Molecular Diagnostics Market? The market for oncology molecular diagnostics has seen considerable growth in recent years. It is anticipated that it will expand from $4.84 billion in 2024 to $5.65 billion in 2025, with a compound annual growth rate (CAGR) of 16.7%. The growth experienced in the historic period is due to factors such as the introduction of early
Top Factor Driving Gaskets, Packing, and Sealing Devices Market Growth in 2025: Surging Oil And Gas Demand Drives Growth In Gaskets, Packing, And Sealing Devices Market
Top Factor Driving Gaskets, Packing, and Sealing Devices Market Growth in 2025: …
How Big Is the Gaskets, Packing, and Sealing Devices Market Expected to Be, and What Will Its Growth Rate Be? In the past few years, the market size of gaskets, packing, and sealing devices has been on a significant upward trend. It is projected to grow from $61.87 billion in 2024 to $66.29 billion in 2025, representing a compound annual growth rate (CAGR) of 7.1%. The notable growth during the historic

All 5 Releases


More Releases for MDS

Plan Your Career as a Dental Assistant: Enroll In MDS Dental Assistance Academy
FOR IMMEDIATE RELEASE Contact Street: 1415 El Camino Real City: San Mateo State: California Post Code: 94402 Country: USA Telephone: 1-888-637-4732 Email: info@mds4rda.com Website: https://dentalassistanceschool.com/ August 18th, 2022, California: Working as a dental assistant is a gateway to a rewarding career and a good thing is that you need not spend years when getting trained in professional schools. It does not take years to complete the training in a dental assistant school near me. All it requires
MDS Dental Assisting Academy Brings Flexible Dental Assisting Courses Online
CONTACT: MDS Dental Assisting Academy Address: 122 Thicket Lane City: Freedom State: California Postcode: 95019 Country: USA Telephone: 1-888-637-4732 Website: https://dentalassistanceschool.com/ Email: info@mds4rda.com California, January 28th, 2022: Are you interested in dentistry? What do you think of a career in dental assisting? If being a dental assistant is your career choice, then an RDA program in MDS Dental Assisting Academy will suit you the best. They provide an interactive course
CASwell Secures Products Against MDS Attacks
New firmware updates for network devices & servers against ZombieLoad, RIDL & Fallout Taipei, Taiwan - August 27th, 2019 - CASwell Inc., a leading manufacturer of innovative and high-performance server solutions for SD-WAN (uCPE/vCPE) and network security systems, announced today that most of its network devices and servers have received updates for their firmware or BIOS making them secure against any malicious attacks based on MDS vulnerabilities. With these updates customers
Myeloidysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Myeloidysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity. Download the sample report @ https://www.pharmaproff.com/request-sample/1162 This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage
Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more
Myelodysplastic Syndrome (MDS) Treatment Market - Global Industry Insights 2025
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around